// App-Quantinova.ai

7009 : Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study.

Researchers

Presenter

  • Carlo Gambacorti-Passerini

Principal Investigators

  • Tim H. Brmmendorf

  • Dong-Wook Kim

  • Yeow Tee Goh

  • Irina S Dyagil

  • Katia Pagnano

  • Arpad Batai

  • Anna G. Turkina

  • Eric Leip

  • Simon Purcell

  • Jocelyn M Leone

  • Andrea Viqueira

  • Jorge E. Cortes

Medical Centers

  • University of Milano-Bicocca, Monza, Italy

  • Uniklinik RWTH Aachen, Aachen, Germany

  • Catholic Hematology Hospital, Seoul St. Mary’s Hospital, Leukemia Research Institute, The Catholic University of Korea, Seoul, South Korea

  • Singapore General Hospital, Singapore, Singapore

  • Singapore

  • National Research Center for Radiation Medicine, Kyiv, Ukraine

  • Hematology and Hemotherapy Center, University of Campinas, Campinas, Brazil

  • Joint St. Stephen and St. László Hospital,Budapest,Hungary

  • National Research Center for Hematology, Moscow, Russia

  • Pfizer Inc., Cambridge, MA

  • Pfizer Ltd, London, United Kingdom

  • Pfizer Spain, Madrid, Spain

  • Georgia Cancer Center, Augusta, GA.

Locations

  • Italy

  • Germany

  • Singapore

  • Ukraine

  • Brazil

  • Hungary

  • Russia

  • United States

  • United Kingdom

  • Spain

Companies

  • Pfizer Inc.

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Myelogenous Leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Bosutinib

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT00261846

  • NCT01903733

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved